Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.

Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP.

Thyroid. 2013 Jun;23(6):683-94. doi: 10.1089/thy.2012.0307.

PMID:
23742290
2.

Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.

Rosário PW, Calsolari MR.

Thyroid. 2014 May;24(5):826-31. doi: 10.1089/thy.2013.0479. Epub 2014 Jan 24.

PMID:
24283207
3.

Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?

Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I.

Surgery. 2012 Dec;152(6):1096-105. doi: 10.1016/j.surg.2012.08.034.

PMID:
23158181
4.

Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.

Kruijff S, Aniss AM, Chen P, Sidhu SB, Delbridge LW, Robinson B, Clifton-Bligh RJ, Roach P, Gill AJ, Learoyd D, Sywak MS.

Surgery. 2013 Dec;154(6):1337-44; discussion 1344-5.

PMID:
24383104
5.

Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.

Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, Chung KW, Ryu JS, Hong SJ, Shong YK, Kim WB.

Eur J Endocrinol. 2013 Nov 22;170(1):23-30. doi: 10.1530/EJE-13-0524. Print 2014 Jan.

6.

The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB.

Cancer. 1998 Jan 15;82(2):375-88.

PMID:
9445196
7.

Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.

Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP.

J Clin Endocrinol Metab. 1997 Nov;82(11):3553-62.

PMID:
9360506
8.

Does extracapsular extension impact the prognosis of papillary thyroid microcarcinoma?

Chéreau N, Buffet C, Trésallet C, Tissier F, Golmard JL, Leenhardt L, Menegaux F.

Ann Surg Oncol. 2014 May;21(5):1659-64. doi: 10.1245/s10434-013-3447-y. Epub 2014 Jan 7.

PMID:
24394985
9.

Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.

Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM.

Thyroid. 2012 Oct;22(10):1007-15. doi: 10.1089/thy.2012.0183. Epub 2012 Aug 8.

PMID:
22873801
10.

Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.

Sohn SY, Choi JY, Jang HW, Kim HJ, Jin SM, Kim SW, Suh S, Hur KY, Kim JH, Chung JH, Kim SW.

Thyroid. 2013 Jun;23(6):741-7. doi: 10.1089/thy.2012.0136.

12.

Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.

Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wygoda Z, Jarzab B.

J Nucl Med. 2007 Jun;48(6):879-88.

13.

[Prospective therapy study in differentiated thyroid carcinoma].

Gemsenjäger E, Heitz P, Martina B.

Schweiz Med Wochenschr. 1995 Nov 18;125(46):2226-36. Review. German.

PMID:
8525342
14.

Radioiodine remnant ablation: current indications and dosing regimens.

Haugen BR.

Endocr Pract. 2012 Jul-Aug;18(4):604-10. doi: 10.4158/EP12117.CO. Review.

PMID:
22849876
15.

Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.

Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, Suh I, C L, Duh QY.

Surgery. 2017 Jan;161(1):127-133. doi: 10.1016/j.surg.2016.05.056. Epub 2016 Nov 14.

PMID:
27855968
16.

Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.

Sacks W, Wong RM, Bresee C, Braunstein GD.

Thyroid. 2015 Apr;25(4):377-85. doi: 10.1089/thy.2014.0298. Epub 2015 Feb 6.

PMID:
25578116
18.

[Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].

Gemsenjäger E, Heitz PU, Martina B, Schweizer I.

Praxis (Bern 1994). 2000 Nov 2;89(44):1779-97. German.

PMID:
11109916
19.

Survival of differentiated thyroid carcinoma studied in 500 patients.

Lerch H, Schober O, Kuwert T, Saur HB.

J Clin Oncol. 1997 May;15(5):2067-75.

PMID:
9164219
20.

An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.

Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):457-80, x. doi: 10.1016/j.ecl.2008.02.007. Review.

PMID:
18502337

Supplemental Content

Support Center